HOME >> MEDICINE >> NEWS
CellCept associated with reduced incidence of cancer, compared to AZA, following heart transplant

San Francisco, April 23, 2004 - A study presented today at an international transplant meeting showed that heart transplant patients treated with the immunosuppressant CellCept (mycophenolate mofetil) in standard immunosuppressive regimens had a significantly lower risk of developing cancer compared to those receiving non-CellCept-based treatment regimens. Presented at the annual meeting of the International Society for Heart and Lung Transplantation (ISHLT), the study found a 27% lower risk of cancer in CellCept-treated patients. Patients studied were part of the ISHLT Transplant Registry. "Though not derived from randomized controlled trials, these data indicate that the choice of maintenance immunosuppressive regimen may be a modifiable risk factor for the development of malignancy in heart transplant recipients," said James O'Neill, M.D., Fellow in Heart Failure and Cardiac Transplantation, Cleveland Clinic.

Previous research had shown that organ transplant recipients receiving immunosuppressive therapy are three to four times more likely to develop tumors than the general population and have an even greater risk of developing certain rare cancers.

Extensive Examination of Registry Validates CellCept Treatment
The study, Mycophenolate Mofetil and the Risk of Developing Malignancy Following Orthotopic Heart Transplantation (OHT), examined competing risk factors to determine which are associated with malignancy following OHT, and was based on 3,895 patients in the ISHLT Transplant Registry. The study examined survival without malignancy in patients taking standard immunosuppressive regimens (defined as cyclosporine or tacrolimus and azathioprine or CellCept), who underwent OHT between January 1, 1995, and December 31, 1997.

Of these patients, 703 (18%) developed malignancy during the follow-up period through June 30, 2002. The breakdown of malignancy was as follows: skin (47%), post-transplant lymphoproliferative disease (10%),
'"/>

Contact: Julip Cantre
Julio.Cantre@ketchum.com
917-204-0599
Ketchum
23-Apr-2004


Page: 1 2 3

Related medicine news :

1. New data supports CellCepts position as a world leader in solid organ transplantation
2. CellCept(R) registry data demonstrated superior long-term organ transplant outcomes
3. CellCepts cardioprotective profile reinforced
4. Data shows life of kidney transplant lengthened by CellCept
5. Organizational traits associated with quality patient care are essential to home care nursing
6. Depression may explain higher risk of heart attack associated with antidepressants
7. Current daily smoking may be associated with increased risk for suicidal thoughts and attempts
8. Inpatient smoking cessation counseling is associated with early differences in mortality
9. Hypothyroidism associated with reduced breast cancer risk
10. COX-2 inhibitors associated with blood pressure elevation
11. Mothers depression associated with increased risk of childs antisocial behavior

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/20/2017)... ... 2017 , ... Adolfson & Peterson Construction (AP) continues to ... a leader in healthcare construction, AP has successfully built several well-known medical facilities ... with Josh now on board. , Josh brings over nine years of ...
(Date:7/20/2017)... ... July 19, 2017 , ... A July 7th article ... worsen, varicose veins in some patients, according to medical experts. Washington State medical ... like excessive sitting or standing, or regularly nicking yourself while shaving your legs, ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... “Lucky the Buffalo and Her Adventures”: a ... of published author, Edward Bieniek. Edward Steven Bieniek Jr. was born in Toledo, Ohio. ... of Toledo at com tech. He is married to a brilliant woman with a ...
(Date:7/18/2017)... ... July 18, 2017 , ... Cognition Corporation ... announced two more sessions of its “From the Helm” Webinar Series. , ... by David Cronin, Cognition’s CEO, the half-hour public webinars will take an in-depth ...
(Date:7/18/2017)... ... ... international clinical trial, led in part by a UC Davis School of Medicine expert, have ... a subgroup of patients. , In a paper just published online in the journal ... countries describe the clinical benefit of using the drug ataluren for a certain group of ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... S.C. , July 10, 2017  BDI ... purchasing and patient support services organization serving specialty ... today the launch of four significant, value-added member ... market insights, better manage reimbursement and improve access ... and factor therapies. ...
(Date:7/6/2017)... , July 6, 2017 ThriveRx, the nutrition division of Diplomat ... families to thrive on nutrition support. To celebrate its anniversary, ... site has a fresh new look with improved organization to create the ... ... "We,ve ...
(Date:7/5/2017)... 5, 2017 Pace Analytical, a company of over 2,000 employees and ... have acquired ESC Lab Sciences, further solidifying their position as the top American ... . ... and CEO of Pace Analytical ... out of Mt Juliet, TN , enhances Pace Analytical,s capability ...
Breaking Medicine Technology:
Cached News: